Welcome to our dedicated page for Bioharvest news (Ticker: BHST), a resource for investors and traders seeking the latest updates and insights on Bioharvest stock.
BioHarvest Sciences Inc (NASDAQ: BHST) leverages its patented Botanical Synthesis technology to revolutionize production of plant-based bioactive compounds. This news hub provides investors and industry professionals with essential updates about the company's dual focus on nutraceutical innovations and pharmaceutical-grade CDMO services.
Access timely reports on clinical advancements, manufacturing partnerships, and regulatory milestones. Our curated collection features verified press releases covering key developments in sustainable production methods, strategic collaborations with global ingredient leaders, and progress in therapeutic compound research.
Bookmark this page for structured updates on BioHarvest's Nasdaq-listed performance, novel health product launches, and breakthroughs in plant cell cultivation technology. All content undergoes rigorous verification to ensure alignment with financial disclosure standards and scientific accuracy.
BioHarvest Sciences (NASDAQ: BHST) closed an upsized underwritten public offering of 2,846,854 common shares at a public offering price of $7.00 per share, including 361,854 shares issued upon exercise of the underwriters' option. Gross proceeds were $19.9 million before underwriting discounts and offering expenses. Craig-Hallum served as sole managing underwriter.
The company said net proceeds will fund additional manufacturing expansion, R&D, marketing, debt reduction or refinancing, capital expenditures, and working capital. Management plans to provide updates on strategic initiatives during its third quarter earnings call on November 13, 2025.
BioHarvest Sciences (NASDAQ: BHST) priced an underwritten public offering of 2,485,000 common shares at $7.00 per share, for gross proceeds of about $17.4 million, before underwriting discounts and expenses.
The company granted the underwriters a 30-day option to buy up to 372,750 additional shares at the public price less the underwriting discount. BioHarvest expects to close the offering on or about November 10, 2025, with Craig-Hallum as sole managing underwriter.
Net proceeds are expected to be used for R&D, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes. The offering is made under a Form F-3 shelf registration declared effective on September 8, 2025.
BioHarvest (NASDAQ: BHST) announced on November 6, 2025 its intent to conduct an underwritten public offering of common stock, with Craig-Hallum as sole managing underwriter.
The company said it may grant the underwriter a 30-day option to buy up to an additional 15% of the shares. Proceeds are expected to be used for R&D, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes. The offering is subject to market conditions and filing of a preliminary prospectus supplement to the SEC.
BioHarvest Sciences (NASDAQ: BHST) will release third quarter 2025 financial results for the period ended September 30, 2025 after market close on Thursday, November 13, 2025. Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on November 13 to discuss Q3 2025 results, provide a corporate update, and hold a Q&A session for telephone participants.
Call details: U.S./Canada dial-in 1-877-300-8521; international dial-in 1-412-317-6026; conference ID 6486821. A telephone playback will be available through Thursday, November 27, 2025 (U.S./Canada replay 1-844-512-2921; international 1-412-317-6671; replay PIN 10204225). A webcast and replay will be available via the company webcast link.
BioHarvest Sciences (NASDAQ: BHST) entered a strategic CDMO partnership with Saffron Tech to develop and commercialize saffron-derived compounds using BioHarvest's patented Botanical Synthesis platform.
Key terms: Saffron Tech will own 75% of developed compositions and IP, BioHarvest will retain 25%. BioHarvest expects Q3 2025 revenue ≈ $9.1M, adjusted EBITDA of ($0.7M) to ($0.4M), cash ≈ $11M as of Sept 30, 2025, and Q4 2025 guidance of $9.0–$9.5M revenue with adjusted EBITDA ($0.6M) to $0.0M. Management highlighted VINIA and CDMO growth and a VINIA BloodFlow Hydration launch on Nov 7, 2025.
BioHarvest Sciences (NASDAQ:BHST) has significantly strengthened its financial position through a series of transactions totaling $14.7 million in balance sheet improvements. The biotechnology company secured $10.9 million in gross proceeds through warrant exercises and convertible note issuances, while simultaneously reducing debt by $3.8 million.
The transactions included $5.8 million raised through warrant exercises, $5.1 million from new convertible notes, and various debt conversions and repayments. The company offered warrant holders and convertible loan holders a reduced price of $6.50 per share. Following these transactions, BioHarvest's total debt stands at $6.6 million.
The proceeds will fund capital expenditures for new capacity building, debt refinancing, and working capital requirements.
BioHarvest Sciences (NASDAQ: BHST) has achieved a significant breakthrough in its Botanical Synthesis platform by successfully producing plant-based exosomes at scale in its bioreactor media. These nano-sized vesicles, naturally secreted by plant cells, offer enhanced absorption and bioavailability compared to regular plant compounds.
The company's bioreactors, which combine optimized growth media with light-permeable technology, produce exosomes containing viniferin, a polyphenol valued for skincare applications. This development positions BioHarvest to enter the global exosome market, projected to grow from $0.7B in 2025 to $2.2B by 2030. The company expects to launch a new skincare application within 18-24 months.
BioHarvest Sciences (NASDAQ: BHST) has announced an upcoming Virtual Investor Webinar scheduled for September 10, 2025, at 1:00 PM ET. CEO Ilan Sobel will lead the presentation, focusing on new capability-building initiatives and the company's strategic 'Big Bets' for the second half of 2025.
The webinar will cover updates on both consumer and CDMO business units, including progress on the Health Pros program, hydration product development, and key CDMO efforts. Participants can join via phone or webcast, with playback available through September 24, 2025.
BioHarvest Sciences (NASDAQ: BHST) reported strong Q2 2025 financial results with revenue growing 41% year-over-year to $8.5 million and gross margins expanding to 60%. The company's VINIA® product line continues to perform well, with 65,000 active U.S. users and over $60 million in cumulative revenue since its 2021 launch.
Key developments include securing new CDMO contracts, launching VINIA® Daily Chews 2X Formula, and advancing three growth initiatives: a Health Pros affiliate program, entry into the electrolyte drinks market, and an AI-enabled CDMO discovery service. Management expects Q3 2025 revenues of at least $9.1 million and projects reaching adjusted EBITDA breakeven in Q4 2025.
BioHarvest Sciences (NASDAQ: BHST), a pioneer in Botanical Synthesis technology, has scheduled its Q2 2025 earnings conference call for August 11, 2025, at 8:00 a.m. Eastern Time. The company will release its financial results for the quarter ended June 30, 2025, before the market opens.
The conference call will include a corporate update and a Q&A session. Participants can join via U.S./Canada dial-in (1-877-300-8521) or International dial-in (1-412-317-6026) using Conference ID 0083058. A replay will be available through August 25, 2025, and can be accessed via webcast or telephone playback.
FAQ
What is the current stock price of Bioharvest (BHST)?
What is the market cap of Bioharvest (BHST)?
